T. Rowe Price Associates
SNDX icon

T. Rowe Price Associates’s Syndax Pharmaceuticals SNDX Stock Holding History

T. Rowe Price Associates’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.5M Buy
107,133
+12,304
+13% +$267K ﹤0.01% 1728
2025
Q4 		$1.99M Buy
94,829
+3,695
+4% +$64.5K ﹤0.01% 1753
2025
Q3 		$1.4M Buy
91,134
+15,730
+21% +$206K ﹤0.01% 1901
2025
Q2 		$706K Buy
75,404
+9,290
+14% +$102K ﹤0.01% 2138
2025
Q1 		$813K Buy
66,114
+9,095
+16% +$128K ﹤0.01% 2056
2024
Q4 		$754K Buy
57,019
+8,092
+17% +$138K ﹤0.01% 2097
2024
Q3 		$942K Buy
48,927
+729
+2% +$15.1K ﹤0.01% 1997
2024
Q2 		$990K Buy
48,198
+3,688
+8% +$77.2K ﹤0.01% 1899
2024
Q1 		$1.06M Buy
44,510
+18,243
+69% +$407K ﹤0.01% 1892
2023
Q4 		$568K Buy
26,267
+1,857
+8% +$28.5K ﹤0.01% 2123
2023
Q3 		$355K Buy
24,410
+1,471
+6% +$27.8K ﹤0.01% 2273
2023
Q2 		$481K Buy
22,939
+11,575
+102% +$241K ﹤0.01% 2151
2023
Q1 		$241K Buy
11,364
+2,000
+21% +$49.8K ﹤0.01% 2445
2022
Q4 		$238K Buy
9,364
+935
+11% +$21.8K ﹤0.01% 2464
2022
Q3 		$203K Buy
+8,429
New +$189K ﹤0.01% 2538
2021
Q4 		– Sell
-516,098
Closed -$9.86M – 3035
2021
Q3 		$9.86M Buy
516,098
+95,678
+23% +$1.59M ﹤0.01% 1419
2021
Q2 		$7.22M Sell
420,420
-18,597
-4% -$341K ﹤0.01% 1456
2021
Q1 		$9.82M Buy
439,017
+267,578
+156% +$6.05M ﹤0.01% 1397
2020
Q4 		$3.81M Buy
+171,439
New +$3.56M ﹤0.01% 1479

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

T. Rowe Price Associates's SNDX Position: Q1 2026 in Review

T. Rowe Price Associates increased its Syndax Pharmaceuticals (SNDX) stake by 13% in Q1 2026, buying an estimated $267K and bringing the position to 107,133 shares worth $2.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1728.

T. Rowe Price Associates first reported a position in SNDX in Q4 2020 and has held it in 19 quarters since. The position peaked at $9.86M in Q3 2021. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • T. Rowe Price Associates held 107,133 shares of Syndax Pharmaceuticals worth $2.5M as of Q1 2026.
  • T. Rowe Price Associates bought 12,304 Syndax Pharmaceuticals shares in Q1 2026, an estimated $267K.
  • Syndax Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1728 holding.
  • T. Rowe Price Associates first reported a position in Syndax Pharmaceuticals in Q4 2020 and has held it in 19 quarters since.
  • T. Rowe Price Associates's Syndax Pharmaceuticals position peaked at $9.86M in Q3 2021.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.